|1.||Høgdall, Claus K: 5 articles (05/2015 - 05/2002)|
|2.||Christensen, Lise: 5 articles (05/2015 - 05/2004)|
|3.||Blaakaer, Jan: 5 articles (05/2015 - 05/2004)|
|4.||Kjaer, Susanne K: 3 articles (05/2015 - 05/2004)|
|5.||Høgdall, Estrid V S: 3 articles (05/2015 - 05/2004)|
|6.||Begum, Farah Diba: 3 articles (06/2010 - 05/2004)|
|7.||Christiansen, M: 3 articles (06/2007 - 04/2004)|
|8.||Ensinger, C: 3 articles (06/2007 - 04/2004)|
|9.||Høgdall, C K: 3 articles (01/2006 - 09/2000)|
|10.||Høgdall, Estrid: 2 articles (06/2010 - 01/2010)|
11/01/1991 - "A significant reduction of plasma tetranectin was found in every malignant tumor type except for mucinous tumors. "
05/01/2009 - "These aims were addressed in the present study by evaluating serum tetranectin (TN) and serum CA125 on a large number of pre- and postmenopausal women with ovarian tumors and controls. "
10/17/1994 - "Tetranectin may be a new prognostic marker which should be included in future clinical studies evaluating the prognosis for cancer patients."
05/01/2009 - "Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors."
10/01/1995 - "Expression of tetranectin appears ubiquitous, although particularly high expression is noted in the stroma of malignant tumors and during mineralization. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2002 - "To study the prognostic value of pre-operative serum tetranectin (TN), CA125 levels and a mathematical formula (Index1) in primary ovarian cancer. "
12/01/2000 - "The aim of the study was to examine the prognostic values of, respectively, tetranectin (TN) and CA-125 measured in serum from patients presenting with relapse of ovarian cancer (OC). "
05/01/2015 - "Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. "
06/01/2010 - "The association between tetranectin (TN) and selected lifestyle factors (smoking and alcohol) and the postoperative complication rate for ovarian cancer (OC) patients undergoing primary cytoreductive surgery has not yet been characterized. "
06/01/2010 - "Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients."
04/01/2004 - "Aberrant tetranectin expression in human breast carcinomas as a predictor of survival."
04/01/2002 - "Overall, the mucinous signet ring carcinomas showed significantly higher tetranectin expression compared to ITA (chi2 = 3.95, p<0.05). "
04/01/2002 - "Of the ten cases of mucinous signet ring cell carcinomas 5 showed high, 3 moderate and 2 low tetranectin expression. "
10/17/1994 - "Lifetables of patients with ovarian carcinoma show that high concentrations of extracellular tetranectin is associated with a poor prognosis. "
10/17/1994 - "While tetranectin is absent in normal extracellular matrix, it is found extracellulary in granulation tissues and in some carcinomas of the breast and the ovary. "
04/01/2002 - "Of the ten cases of well-differentiated intestinal type adenocarcinomas (ITA) 4 showed moderate regional, 3 low regional and 3 negative tetranectin expression. "
04/01/2002 - "The aim was to analyze the immunohistochemical localization of tetranectin in gastric adenocarcinomas and the adjacent tissues of the wall of the stomach. "
04/01/2002 - "Tetranectin expression in gastric adenocarcinomas."
09/01/2000 - "Serum tetranectin and CA125 in endometrial adenocarcinoma."
11/01/1994 - "In normal colonic mucosa tetranectin staining was predominantly found in the goblet cells whereas in adenocarcinomas this staining was confined to the tumour stroma. "
|5.||Breast Neoplasms (Breast Cancer)
01/01/1993 - "Prognostic value of serum tetranectin in patients with metastatic breast cancer."
01/01/1993 - "To evaluate serum tetranectin as a prognostic marker before first-line chemotherapy, serum levels were studied in 67 patients with metastatic breast cancer. "
01/01/1992 - "The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix."
01/01/1992 - "The immunohistochemical studies of fibronectin, laminin and tetranectin, on which this thesis is based, were undertaken in order to investigate if qualitative or quantitative changes of these proteins between benign and malignant breast tissue would reflect the net effect of the different inherent characteristics of breast cancer cells known from experimental studies (i.e. "
|2.||Proteins (Proteins, Gene)
|3.||Plasminogen Activator Inhibitor 1
|5.||Plasminogen Activator Inhibitor 2
|9.||Apolipoprotein A-I (Apolipoprotein A1)
|10.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)